Company / R&D Expense
Biogen R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.8B
FY2025
5-year range
$1.8B / $2.5B
FY2021-FY2025
Trend
-10.2%
vs FY2024
Sector context
#13 of 209
Health Care
What the data says
Among 209 Health Care companies, Biogen is in the top 6% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $1.8B in FY2025 to $4.0B in FY2020.
Based on SEC 10-K filings.
$1.8B in FY2025 with a 5-year CAGR of -14.9%. Top quartile in the Health Care sector.
Declined from $2.4B to $1.8B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -7.3%
- 5-Year CAGR
- -14.9%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 209This company $1.8B Sector average $647.6M
▼
+174.6% above sector average
Key checks
Key Insights
- 5-year CAGR of -14.9%, indicating a declining trend.
- In FY2025, r&d expense decreased 10.2% year-over-year.
- Ranks #13 out of 209 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8B | -10.2% |
| FY2024 | $2.0B | -19.0% |
| FY2023 | $2.4B | +9.6% |
| FY2022 | $2.2B | -10.8% |
| FY2021 | $2.5B | -37.3% |
| FY2020 | $4.0B | +75.0% |
| FY2019 | $2.3B | -12.2% |
| FY2018 | $2.6B | +15.2% |
| FY2017 | $2.3B | +14.2% |
| FY2016 | $2.0B | -2.0% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026